Michael Xu

Mr. Michael Xu

Thomas Jefferson University, Philadelphia, Mississippi, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
BRBenjamin E. Rubin
Benjamin E. Rubin
SDSpencer Diamond
Spencer Diamond
BCBrady F. Cress
Brady F. Cress
ACAlexander Crits-Christoph
Alexander Crits-Christoph
CHChristine He
Christine He
JDJennifer A. Doudna
Jennifer A. Doudna
Knowledge of microbial gene functions comes from manipulating the DNA of individual species in isolation from their natural communities. While this approach to microbial genetics has been foundational, its requirement for culturable microorganisms has left the majority of microbes and their interactions genetically unexplored. Here we describe a generalizable methodology for editing the genomes of specific organisms within a complex microbial community. First, we identified genetically tractable bacteria within a community using a new approach, Environmental Transformation Sequencing (ET-Seq), in which non-targeted transposon integrations were mapped and quantified following community delivery. ET-Seq was repeated with multiple delivery strategies for both a nine-member synthetic bacterial community and a ~200-member microbial bioremediation community. We achieved insertions in 10 species not previously isolated and identified natural competence for foreign DNA integration that depends on the presence of the community. Second, we developed and used DNA-editing All-in-one RNA-guided CRISPR-Cas Transposase (DART) systems for targeted DNA insertion into organisms identified as tractable by ET-Seq, enabling organism- and locus-specific genetic manipulation within the community context. These results demonstrate a strategy for targeted genome editing of specific organisms within microbial communities, establishing a new paradigm for microbial manipulation relevant to research and applications in human, environmental, and industrial microbiomes.

3 September 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
FJFuguo Jiang
Fuguo Jiang
JLJun-Jie Liu
Jun-Jie Liu
BOBeatriz A. Osuna
Beatriz A. Osuna
Michael XuMichael Xu
Michael Xu
JBJoel D. Berry
Joel D. Berry
JDJennifer A. Doudna
Jennifer A. Doudna
SUMMARY: CRISPR–Cas immune systems utilize RNA-guided nucleases to protect bacteria from bacteriophage infection. Bacteriophages have in turn evolved inhibitory ‘anti-CRISPR’ (Acr) proteins, including six inhibitors (AcrIIA1-6) that can block DNA cutting and genome editing by type II-A CRISPR-Cas9 enzymes. We show here that AcrIIA2 and its homologue, AcrIIA2b, prevent Cas9 binding to DNA by occluding protein residues required for DNA binding. Cryo-EM-determined structures of AcrIIA2 or AcrIIA2b bound to S. pyogenes Cas9 reveal a mode of competitive inhibition of DNA binding that is distinct from other known Acrs. Differences in the temperature dependence of Cas9 inhibition by AcrIIA2 and AcrIIA2b arise from differences in both inhibitor structure and the local inhibitor-binding environment on Cas9. These findings expand the natural toolbox for regulating CRISPR-Cas9 genome editing temporally, spatially and conditionally.

4 March 2026 in Current Medical Research and Opinion
Verified
Journal Article
Open access
APAndrew Jay Portuguese
Andrew Jay Portuguese
TITimothy J. Inocencio
Timothy J. Inocencio
PQPeter Quon
Peter Quon
JHJames Harnett
James Harnett
ZZZheng-Yi Zhou
Zheng-Yi Zhou
QMQiufei Ma
Qiufei Ma
To evaluate the total cost of care, average monthly treatment cost, and cost per outcome of linvoseltamab versus teclistamab and elranatamab in triple-class-exposed relapsed/refractory multiple myeloma (RRMM) using matching-adjusted indirect comparisons (MAICs). Total cost per patient and cost per outcome were estimated over 1- and 2-year time horizons from a United States commercial payer perspective. Cost components included drug acquisition, administration, monitoring, adverse events, progression, and death. Dosing schedules were applied per prescribing information, aligning with pivotal trial-based MAIC-adjusted clinical inputs. Costs were sourced from databases and published literature. The 1- and 2-year cumulative costs were $387,773 and $488,088 with linvoseltamab versus $500,670 and $639,013 with teclistamab; costs per progression-free (PF) month were $40,904 and $29,036 versus $63,057 and $50,877; costs per overall response were $538,573 and $677,901 versus $794,714 and $1,014,307. The 1- and 2-year cumulative costs were $383,368 and $472,907 with linvoseltamab versus $416,359 and $475,918 with elranatamab, for adjusted median treatment durations of 11.3 versus 5.6 months; 1- and 2-year costs per PF month were $43,417 and $29,912 versus $50,529 and $33,304, while costs per overall response were $539,955 and $666,066 versus $682,556 and $780,193. Linvoseltamab had lower total costs and cost per outcome than teclistamab at 1- and 2-year timepoints. Linvoseltamab had comparable total costs to elranatamab despite longer treatment duration, and consistently lower costs per outcome. Within this exploratory MAIC model, linvoseltamab was associated with lower economic burden in heavily pretreated RRMM. These results should be interpreted considering study assumptions and limitations.